Article
Non-fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX.
Journal of thrombosis and haemostasis : JTH - 1 Jul 2004
van der Heijden J F, Rekké B, Hutten B A, van der Meer F J M, Remkes M G H, Vermeulen M, Büller H R, Reitsma P H
Abstract excerpt
BACKGROUND AND OBJECTIVES: The key complication of treatment with vitamin K antagonists (VKAs) is bleeding. The major determinant of VKA-induced bleeding is the intensity of anticoagulation. Individual patient characteristics may also influence bleeding risk. In addition, soluble thrombomodulin (s-TM) levels and mutations in the propeptide of factor (F)IX are important candidate risk factors in this respect....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.